-
"Targeted + immune" combination therapy Cabometyx + Tecentriq suffered an amazing failure
Time of Update: 2021-08-09
Recently, Exelixis announced the clinical trial data of tyrosine kinase inhibitor (TKI) Cabometyx and Roche immuno-oncology therapy (IO) Tecentriq for the first-line treatment of hepatocellular carcinoma (HCC) .
-
Eli Lilly and Novo Nordisk provide the latest research positive data on type 2 diabetes
Time of Update: 2021-08-09
A few days ago, foreign media reported that Eli Lilly’s diabetes research drug showed great promise in reducing the level of glycosylated hemoglobin (A1C) and weight loss in patients with type 2 diabetes (including patients who have never received the disease before) .
-
[JMC] You Qidong/Wang Lei, etc.: Research progress of small molecule targeting serine protein phosphatase (PPPases)
Time of Update: 2021-08-08
Although they play a common mechanism of dephosphorylation through highly conserved catalytic active sites, different pppases show specificity according to their different regulatory subunits or unique structural features, which provides potential for the rational design of small molecules.
-
The mid-term results of RNAi therapy are positive, which may break the non-alcoholic steatohepatitis (NASH) drug-free situation
Time of Update: 2021-08-08
AROHSD1001 is a phase I/II single-dose and multiple-dose escalation study, the purpose is to evaluate the RNA interference (RNAi) therapy ARO-HSD in normal healthy volunteers and patients with non-alcoholic steatohepatitis (NASH) or patients with suspected NASH Safety, tolerability, pharmacokinetics and pharmacodynamic effects .
-
Hepatotoxicity mechanism of tumor immunotherapy: macrophages and neutrophils
Time of Update: 2021-08-08
On July 1, 2021, the journal Science Immunology published a study by scientists at the Massachusetts General Hospital of Harvard Medical School, which proved that liver macrophages (Kupffer cells) are the key cause of liver toxicity in mediating immunotherapy .
-
The world's first 14-valent HPV vaccine! Shenzhou cell SCT1000 enters the clinic
Time of Update: 2021-08-08
Recently, Shenzhou Cell announced that its self-developed 14-valent HPV vaccine SCT1000 has entered clinical phase I/II studies and completed the enrollment of all 80 subjects .
It is worth noting that this is the world's first 14-valent HPV vaccine to enter the clinical research phase .
-
Talking about the development of Me-too drugs through case analysis
Time of Update: 2021-08-08
Even if the company invests huge amounts of money in technology updates, its sales are still far from keeping up with the rapid growth of new drug research and development costs .
-
Cinda Biologics FGFR inhibitor pemigatinib tablets submitted for marketing
Time of Update: 2021-08-07
The listing application of pemigatinib in China is based on a case of unresectable locally advanced, recurrent or metastatic cholangiocarcinoma subjects who have failed at least first-line systemic treatment in the past, accompanied by FGFR2 fusion or rearrangement, and unresectable.
-
"Gene Magic Scissors" CRISPR announced the results of in vivo clinical trials, and many gene editing stocks soared!
Time of Update: 2021-08-07
On June 26, Intellia Therapeutics (hereinafter referred to as Intellia) and Regeneron jointly announced that the in vivo CRISPR/Cas9 gene editing drug NTLA-2001 Phase I clinical trial has achieved positive results .
-
Shandong pharmaceutical company Fawei enters 400 million blockbuster products for skin diseases
Time of Update: 2021-08-07
Source: CDE official website, Minet database Medical Network, July 9 News On July 8, Shandong Dyne Marine Biopharmaceuticals and Shandong Liangfu Pharmaceuticals submitted applications for the imitation of tacrolimus ointment in four categories and were accepted .
-
Hengrui's heavy personnel changes!
Time of Update: 2021-08-07
Zhou Yunshu applied to resign from the company’s chairman, general manager and the corresponding positions of the special committees of the board due to physical reasons , The resignation report will take effect from the day it is delivered to the company’s board of directors .
-
Hongri Pharmaceuticals will win the best-selling anti-Parkinson's disease drug to hit the over 2.5 billion market
Time of Update: 2021-08-07
Hospital hospital hospital pharmacy pharmacy pharmacy In the competitive landscape of terminal anti-Parkinson drug products in China's public medical institutions in 2020, pramipexole hydrochloride tablets ranked first with about 33% market share, and pramipexole hydrochloride sustained-release tablets ranked first with about 5% market share.
-
China Resources Pharmaceutical plans to acquire 10% equity of Yongtai Biotechnology for HK$800 million
Time of Update: 2021-08-06
Limited, Ren Xiaojuan and BeiNi Ltd (as the seller) ) Entered into a share purchase agreement, pursuant to which the buyer conditionally agreed to purchase and the seller conditionally agreed to sell Wing Tai Biopharmaceutical Co.
-
Maytansine-the alloy warhead from non-medicinal to ADC!
Time of Update: 2021-08-06
In recent years, the use of ADC in targeted therapy of tumors has received great attention from the pharmaceutical industry; among them, ADC drugs that use maytansine derivatives as cytotoxic components are favored by researchers, and have achieved a A breakthrough in the series .
-
BioPharma Dive: Progress and competition in gene therapy for sickle cell disease
Time of Update: 2021-08-06
Gene therapies developed by Bluebird Bio, CRISPR Therapeutics, and Vertex Pharmaceuticals have shown promising signs, although further tests are needed to better understand whether they have limitations or whether their effects will disappear over time , But basically can eliminate the vascular occlusion crisis .
-
The subject has serious complications!
Time of Update: 2021-08-06
Sigilon revealed on Friday that recruitment for the Phase 1/2 study of cell therapy SIG-001 has been stopped and related investigations are ongoing .
FDA puts Sigilon's hemophilia cell therapy trial on hold thanks to safety concerns 2.
-
Orient Pharmaceuticals: Pregabalin passed the drug GMP compliance inspection
Time of Update: 2021-08-06
On July 22, Oritech issued an announcement stating that the company learned from the Zhejiang Provincial Food and Drug Administration website that pregabalin passed the drug GMP compliance inspection results and is mainly used for the treatment of post-herpetic neuralgia and fibromyalgia .
-
NEJM: Real-world research data of Kexing inactivated vaccines released for the first time
Time of Update: 2021-08-06
This is the first real-world research result of Kexing's inactivated new crown vaccine published so far.
. The results of the study show that in the real world, Coxing's new crown vaccine effectively prevents Covid-19, including serious illness and death.
-
Gale FASN Inhibitor Approved for Phase 3 Clinical Tumor Indication
Time of Update: 2021-08-06
On July 22, Gallée announced that the National Medical Products Administration (NMPA) of China has approved a Phase 3 clinical trial of ASC40 combined with bevacizumab in the treatment of patients with recurrent glioblastoma (rGBM) .
-
Baiyunshan norfloxacin tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-08-06
According to the announcement, the Norfloxacin Tablets of Baiyunshan General Pharmaceutical Factory were officially launched in China on August 29, 1991, and the consistency evaluation application was submitted to the National Medical Products Administration on November 18, 2019.
